News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
CV Technologies Inc. Release: News Conference Notice: Results of Four City Study on COLD-FX Involving 780 Participants to Be Discussed by Principal Investigator, Dr. Gerald Predy and Company Officials
September 15, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
EDMONTON, ALBERTA--(Marketwire - Sept. 15, 2008) - CV Technologies Inc. (TSX:CVQ) - WHAT: News Conference to discuss results of COLD-FX's biggest trial to date.
Twitter
LinkedIn
Facebook
Email
Print
Events
MORE ON THIS TOPIC
Alzheimer’s disease
Eisai Still Confident in Anti-Tau Asset as J&J Becomes Latest Victim in Spiraling Space
December 5, 2025
·
4 min read
·
Heather McKenzie
Cardiovascular disease
Amgen’s Repatha Cuts Risk of First Heart Attack by 36% in Phase III Trial
November 10, 2025
·
4 min read
·
Heather McKenzie
Immunology and inflammation
Novartis Presents New Data From Potential First Targeted Sjögren’s Treatment
October 29, 2025
·
3 min read
·
Heather McKenzie
Cell and Gene Therapy
Meeting on the Mesa Arrives Amid Mixed Signals for Cell and Gene Therapy
October 6, 2025
·
5 min read
·
Ben Hargreaves
